FDMT NASDAQ
4D Molecular Therapeutics, Inc.
1W: -5.5%
1M: -8.5%
3M: +7.5%
YTD: +86.8%
1Y: +56.6%
3Y: +5.0%
5Y: -61.1%
$13.67
-0.17 (-1.23%)
Weekly Expected Move ±7.2%
$12
$13
$14
$15
$16
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships3
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2023-07-11
Earliest Filing
2025-10-31
Latest Filing
partner: 2
licensee: 1
Counterparties (Filed by FDMT)
3 relationshipsCompanies named in FDMT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Otsuka Pharmaceutical Co., Ltd. | — | partner | Collaboration and License Agreement for exclusive rights to develop and commercialize 4D-150 in APAC markets | 2025-10-31 | View |
| Leerink Partners LLC | — | partner | Sales Agent for the Company's at-the-market offering of common stock | 2024-06-07 | View |
| Astellas Gene Therapies, Inc. | — | licensee | 4D Molecular Therapeutics granted an exclusive worldwide license for its R100 vector technology to Astellas Gene Therapi | 2023-07-11 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-28 | Other Events | View | |
| 2026-08-13 | Earnings Release | View | |
| 2026-07-20 | Other Events | View | |
| 2026-06-29 | Material Agreement; Financial Obligation | Agreement | View |
| 2026-06-22 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-01-26 | Unregistered Sales of Equity Securities; Financial Statements and Exhibits | View | |
| 2026-01-07 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-12-10 | Other Events | View | |
| 2025-11-17 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-07 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Other Events | View | |
| 2025-10-31 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-10-02 | Departure/Election of Directors; Appointment of Officers; Amendments to Articles of Incorporation or | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-02 | Departure/Election of Directors; Appointment of Officers; Other Events | View | |
| 2025-06-20 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-28 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR